Jim Lisbakken, a partner and Co-Chair of the firm's Technology Transactions
& Privacy practice, focuses on business transactions, licensing, and joint
ventures and corporations specifically in the life sciences and technology
industries. He has experience serving as outside general counsel to boards of
directors of public and private companies, and has advised clients on numerous
strategic alliances and technology agreements with Eli Lilly, GlaxoSmithKline,
Serono, Johnson & Johnson, Abbott Laboratories and other international life
sciences companies. Jim also has experience with financing transactions,
acquisitions and spin-outs.
- Biotechnology Law (Intellectual Property, Licensing, Life Sciences, Pharmaceutical, Transactions)
- Corporate Law
- Mergers and Acquisitions Law
- Technology Law
"Since 1985, I have worked with Jim in my capacity as general counsel to three public companies and CEO of two private ones. He is a superb, highly skilled transactional attorney with exceptional expertise in the field of biotechnology. Having Jim on my team has ensured the highest level of success in favorably concluding numerous complex transactions. Any firm represented by Jim is truly fortunate to have the services of one of the finest attorneys in America."
"I have worked with Jim on a number of transactions over the past four to five years in my role as Vice President of Business Development at AnorMED. Jim has been an excellent partner in all my licensing and business transactions.
I found that he had a very broad knowledge base and experience in pharmaceutical licensing and general corporate maters. Jim's drafting skills were superb, and his attention to detail was superior. He showed a high level of commitment to all our projects and helped us keep our timelines in all our transactions, despite some inconvenient last-minute requests.
I have enjoyed my time working on projects with Jim, and have appreciated the high standards to which he holds himself, his strong work ethic, and his high level of integrity.
Write a client comment